Pfizer PFE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.45B-17.7% | $17.56B+5.4% | $16.65B+13.7% | $14.65B+6.8% | $13.72B-22.8% | ||
| $3.55B-32.7% | $5.27B+26.4% | $4.17B+10.4% | $3.78B+32.8% | $2.85B-51.9% | ||
| $10.9B-11.2% | $12.29B-1.6% | $12.48B+14.8% | $10.88B0.0% | $10.87B-8.3% | ||
| 75.4%+5.5pp | 70%-5.0pp | 74.9%+0.7pp | 74.2%-5.0pp | 79.3%+12.5pp | ||
| $2.96B-28.9% | $4.16B+30.6% | $3.19B-6.7% | $3.42B+12.7% | $3.03B-29.1% | ||
| $1.61B+31.1% | $1.23B+0.6% | $1.22B+1.0% | $1.21B0.0% | $1.21B-10.9% | ||
| $3.17B— | —— | $3.33B+9.5% | $3.04B+9.3% | $2.79B— | ||
| $461M+23,150% | -$2M+99.1% | -$216M-253% | $141M+175% | -$189M+55.1% | ||
| $2.69B— | —— | $3.54B+21.7% | $2.91B-1.9% | $2.97B+624% | ||
| 18.6%— | —— | 21.3%+1.4pp | 19.9%-1.8pp | 21.6%+19.3pp | ||
| -$13M— | $0— | $0-100% | $25M— | $0-100% | ||
| $0.47— | —— | $0.62+21.6% | $0.51-1.9% | $0.52+643% | ||
| $0.47— | —— | $0.62+21.6% | $0.51-1.9% | $0.52+643% | ||
| 5.7B+0.3% | 5.7B0.0% | 5.7B+0.1% | 5.7B-0.1% | 5.7B+0.2% | ||
| 5.7B+0.1% | 5.7B0.0% | 5.7B0.0% | 5.7B+0.2% | 5.7B+0.2% | ||
| $2.34B-9.4% | $2.58B+12.4% | $2.3B+1.1% | $2.27B+7.6% | $2.11B-6.0% | ||
| $1.18B-3.8% | $1.23B+0.6% | $1.22B+1.0% | $1.21B0.0% | $1.21B-10.9% | ||
| $100M-83.5% | $605M+112% | $286M+1,689% | -$18M-103% | $678M-9.6% | ||
| $72M-92.9% | $1.02B+471% | $178M-94.7% | $3.34B+2,098% | $152M-64.9% | ||
| $0.48— | —— | $0.62+21.6% | $0.51-1.9% | $0.52+643% | ||
| $0.47— | —— | $0.62+21.6% | $0.51-1.9% | $0.52+643% | ||
| $0.00— | $0.00— | $0.00— | $0.00— | $0.00— | ||
| -$12M+97.2% | -$433M+43.4% | -$765M-181% | -$272M+59.0% | -$663M-67.4% | ||
| $72M-92.9% | $1.02B+471% | $178M-94.7% | $3.34B+2,098% | $152M-64.9% | ||
| $293M-70.1% | $981M+257% | $275M-75.7% | $1.13B+220% | $353M-74.7% | ||
| $62M+37.8% | $45M-31.8% | $66M— | —— | $74M-49.7% | ||
| -$2.86B— | $0+100% | -$2.48B+22.5% | -$3.2B+38.9% | -$5.23B-2.2% | ||
| $785M+113% | -$6.15B-153% | -$2.43B-162% | $3.95B+20.7% | $3.27B— | ||
| $2.62B-51.1% | $5.35B+16.2% | $4.6B— | $0-100% | $2.34B-65.3% | ||
| $93M-20.5% | $117M-59.9% | $292M+189% | $101M+353% | -$40M-102% | ||
| -$861M+80.9% | -$4.51B-773% | -$517M+30.0% | -$739M+22.5% | -$953M+59.6% | ||
| -$22M— | —— | -$14M— | —— | -$300M-1,900% | ||
| $792M— | —— | $583M— | —— | $3.85B+891% | ||
| $436M-48.4% | $845M+40.4% | $602M-2.6% | $618M+9.6% | $564M-38.5% | ||
| $2.57B-36.5% | $4.05B-4.1% | $4.22B+29.5% | $3.26B+15.6% | $2.82B-54.3% | ||
| -$284M-560% | -$43M-13.2% | -$38M-81.0% | -$21M+94.1% | -$356M-2,443% | ||
| -$127M— | —— | —— | -$517M-33.9% | -$386M— | ||
| $88M-85.1% | $591M+64.6% | $359M+470% | $63M-23.2% | $82M+183% | ||
| $0— | —— | —— | —— | $6.31B+77.8% | ||
| $0— | —— | —— | $151M-92.6% | $2.05B-40.7% | ||
| $2.49B-22.3% | $3.21B+25.9% | $2.55B+2.6% | $2.48B+12.7% | $2.2B-27.4% | ||
| $272M+20.9% | $225M+11.9% | $201M-1.0% | $203M+19.4% | $170M-4.0% | ||
| $2.45B0.0% | $2.45B0.0% | $2.44B0.0% | $2.45B+0.3% | $2.44B+2.4% | ||
| $4.78B— | —— | $5B+7.0% | $4.67B+6.0% | $4.4B+146% | ||
| 33.1%— | —— | 30%-1.9pp | 31.9%-0.2pp | 32.1%+22.0pp | ||
| $3.17B— | —— | $3.33B+9.5% | $3.04B+9.3% | $2.79B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pfizer's revenue?
- Pfizer (PFE) generated $63.3B in revenue over the trailing twelve months, up 1.4% year over year.
- Is Pfizer profitable?
- Pfizer reported $12.1B in net income over the trailing twelve months, a 15.7% net margin.
- What is Pfizer's earnings per share?
- Pfizer's diluted EPS over the trailing twelve months is $2.12.
- Where does Pfizer's income statement data come from?
- Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
